Are China’s vaccines already being used in Zimbabwe under WHO probe?

Are China’s vaccines already being used in Zimbabwe under WHO probe?

The newspaper went on to quote WHO country representative Alex Gasasira as saying experts were already in China to study the Sinovac and Sinopharm COVID-19 vaccines.

“Those are still undergoing evaluations by WHO, and until the experts give a comprehensive report there is not much that we can say. Experts from WHO have been sent to China for the assessment,” Gasasira is quoted saying.

WHO Evaluation

The WHO evaluation which Gasasira referred to is a mandatory procedure for all candidate vaccines, which was first developed in response to the ebola outbreak of 2014-16. The evaluation was not prompted by Gao’s comments. The WHO has not announced any mission to China for that purpose.

WHO, through its Department of Regulation and Prequalification (RPQ), undertakes the emergency use listing process to guide United Nations agencies and member states on the acceptability, for purchase and use, of vaccines.

The assessment is meant to provide assurance that candidate vaccines meet the WHO standards on quality, safety and efficacy.

On March 13, the Strategic Advisory Group of Experts (SAGE), which advises the WHO on vaccines, announced that Sinopharm and Sinovac had presented data indicating levels of efficacy compatible with WHO requirements.

To date, four vaccine candidates have received WHO emergency use approval, out of 19 within the global health watchdog’s evaluation framework. These are Pfizer-BioNTech, Johnson & Johnson and two versions of the AstraZeneca vaccine.

According to a WHO schedule, emergency use approvals could be granted to Sinovac, Sinopharm and Moderna by the end of April 2021.

All these vaccines are currently being administered after they received approvals in the various countries.

For instance, while the Moderna vaccine is still under WHO assessment, the US Food and Drug Administration (FDA) approved its use in December 2020.

CONCLUSION:

NewsDay’s reporting that a Chinese official’s “admission” of low efficacy has triggered a WHO investigation into Chinese vaccines is erroneous as it is based on a disputed interpretation of what he said. The article is also based on a misreading of the global health watchdog’s mandatory vaccine evaluation process, which was already underway long before the contested “admission” was made.

(323 VIEWS)

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *